BRD4 (BD1/2) BET bromodomain inhibitor

wound-heal. at 1 mpk QD, bell-shaped pharm.

from phenotypic screen (MDM2 inhibitor hit)

Nat. Chem. Biol., Jan. 18, 2021

Novartis (NIBR), Basel, CH

The Novartis BET bromodomain inhibitor, NVS-BET-1, is a new chemotype of BRD4 (BD1 and BD2) inhibitor. While we recently highlighted a few high-profile, selective bromodomain inhibitors from AbbVie and…


 become a member to continue reading

Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.

  • Stay up-to-date and save more time with exclusive members-only content
  • On-board new team members with educational content and case studies
  • Generate ideas and discussion with easy-to-read slide decks
  • Generate ideas and discussion with easy-to-read slide decks